Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A

Figure 1

Mean plasma concentration-time profile of StA in three different formualtions by intravenous or intragastric administration (Mean ± SD, ). (a) Intragastric administration of TPAP formulation; (b) intravenous administration of DPS formulation; ((c) and (d)) intragastric and intravenous administration of nanoemulsion formulation.

(a)

(b)

(c)

(d)